# Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic P

Source: https://onco.cc/trials/nct06454448/  
OnCo record `nct06454448` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of adebrelimab and decitabine in pancreatic cancer, run by Tianjin Medical University Cancer Institute and Hospital, now recruiting.

## Summary

Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer is a phase 1/2, interventional study registered as NCT06454448 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 20 participants, started 2024-06-15 and due to reach its primary completion in 2025-06. Interventions recorded: Adebrelimab;decitabine;. Conditions listed: Adebrelimab (SHR-1316); Decitabine; Metastatic Pancreatic Cancer. Primary outcome: Dose Limiting Toxicity (DLT); The recommended phase 2 dose (RP2D); Objective Response Rate (ORR). Pancreatic eligibility wording from the registry: "Histologically or cytologically confirmed diagnosis of pancreatic cancer (originating from the pancreatic ductal epithelium), with clinical records showing metastatic pancreatic cancer (stage IV according to the AJCC 8th edition TNM staging of pancreatic cancer); 3". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06454448
- Phase: 1/2
- Setting: Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer
- Sponsor: Tianjin Medical University Cancer Institute and Hospital
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT06454448: https://clinicaltrials.gov/study/NCT06454448

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [Decitabine](https://onco.cc/drugs/decitabine/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06454448.json